These results suggested that the CD4+T, CD8+T, and NK cells are all essential for the antitumor immunity of the ADSC-E7’-eGFP–PE(ΔIII)-E7-KDEL3 combined treatment, and that the effect of tumor inhibition might be achieved by the CD8+ T cells. The gene discussed is CD4; the disease is neoplasm.